Leber’s Hereditary Optic Neuropathy

About the Study:
Sponsored by Santhera Pharmaceuticals, the purpose of this multi-center study, called LEROS, is to assess the safety and effectiveness of long-term treatment with Idebenone (Raxone) in Leber’s Hereditary Optic Neuropathy (LHON).

All participants enrolled will receive study treatment with Idebenone.

Participants participating in this study will have approximately 9 scheduled study visits over a period of 25 months. Each visit will last about 1-3 hours.

Key Inclusion Criteria:
- Age ≥ 12 years
- Impaired visual acuity in affected eyes due to LHON
- Onset of symptoms ≤ 5 years

Key Exclusion Criteria:
- History of previous idebenone use
- Women who are pregnant or breastfeeding

For Additional Information or To Refer A Patient, Contact:
Principal Investigator: Steven Newman, MD
Study Coordinators: Ashton Leone, MPH, CCRP at (434) 243-5737 or aml7q@virginia.edu
Tamika Mercer, COA at (434) 243-2852 or tmm2v@virginia.edu
Allison Weiderhold at (434) 243-2921 or alw5rm@virginia.edu